Ginkgo bioworks stocks.
The honeymoon for newly minted Ginkgo Bioworks ( DNA 4.11%) shares recently came to an abrupt end, and it didn't take long. The synthetic-biology start-up just made its stock market debut in mid ...
Ginkgo Bioworks' (NYSE: ... will probably keep Ginkgo's stock under pressure throughout 2023. Figure 9: Ginkgo Bioworks Revenue (Source: Created by author using data from Ginkgo Bioworks) ...Ginkgo Bioworks Holdings Inc stock has a Value Score of 6, Estimate Revisions Score of 34 and Quality Score of 13. Comparing Arcellx Inc and Ginkgo Bioworks Holdings Inc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s …Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. On that note, on August 29 Ginkgo Bioworks (DNA 3.88%) announced that it is joining forces with Alphabet, ... But does the work with Alphabet make it a buy, or is this stock still too risky to touch?Ginkgo Bioworks’ Bottom-Line Results Are Getting Worse. More important than whether Wood is buying DNA stock is the question of whether Ginkgo Bioworks is a financially sound business.
Oct 6, 2021 ... In about an hour following the publication of Scorpion's 175-page report, Ginkgo's stock price dropped at least 20%, down to about $9.50 a share ...While Ginkgo Bioworks is an exciting company, the pricing of the SPAC stock leaves a lot of room for things to go wrong between now and the company's long-term projections.
Ginkgo Bioworks ( DNA -7.19%) is a biotech that's operating on multiple bleeding edges of innovation as it works to engineer and manufacture biological cells at scale. Between its highly automated ...Ginkgo Bioworks (NYSE:DNA) operates at the frontier of synthetic biology. This biotech company efficiently crafts organisms for various applications, from protein development to enzyme creation.
2. Ginkgo Bioworks. Ginkgo Bioworks ( DNA -7.19%) also plans to be a collaboration-driven business, but its approach is a bit different. While it uses its machine learning platform to help with ...Oct 6, 2021 ... In about an hour following the publication of Scorpion's 175-page report, Ginkgo's stock price dropped at least 20%, down to about $9.50 a share ...Ginkgo is expecting Total revenue of $250 - $260 million in 2023. Ginkgo revised its expectations for Cell Engineering revenue to $145 - $150 million in 2023, inclusive of $4 million of downstream ...Future criteria checks 2/6. Ginkgo Bioworks Holdings is forecast to grow earnings and revenue by 48.1% and 23.5% per annum respectively. EPS is expected to grow by 48.5% per annum. Return on equity is forecast to be -86.5% in 3 years.
Find out the direct holders, institutional holders and mutual fund holders for Ginkgo Bioworks Holdings, Inc. (DNA).
Find the latest Ginkgo Bioworks Holdings, Inc. (DNA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Dec 1, 2023 · See the latest DNA Stock price for Ginkgo Bioworks Holdings Inc and NYSE: DNA stock rating, related news, valuation, dividends and more to help you make your investing decisions. 10 stocks we like better than Ginkgo Bioworks When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor ...Ginkgo Bioworks (NYSE:DNA) Is among the more prominent stocks in the synthetic biology space. The company is located in Boston, Massachusetts, which is a leading hub in the biotechnology industry.Shares of Ginkgo Bioworks ( NYSE: DNA) added ~10% pre-market Tuesday after the cell platform company and Google Cloud, a unit of tech giant Alphabet Inc. ( NASDAQ: GOOG) ( NASDAQ: GOOGL ...Cutting-edge biotech company Ginkgo Bioworks Holdings ( DNA -4.79%) was a popular stock on Tuesday. The cell engineering specialist's share price zoomed more than 7% higher today, thanks to ...Sep 27, 2023 · Ginkgo Bioworks. Market Cap. $3B. Today's Change. (5.80%) $0.08. Current Price. $1.46. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ ... Apr 12, 2023 · Boston-based Ginkgo Bioworks (NYSE: DNA) is working to develop a platform to “program cells to make everything from food to materials to therapeutics.” Industries it serves include agriculture ...
49.41M. AMZN. 145.18. +1.65%. 47.06M. View today's Ginkgo Bioworks Holdings stock price and latest DNA news and analysis. Create real-time notifications to follow any changes in the live stock price.Stock Quote. Price. $1.39. Volume. 65. Change. -0.07. % Change. -4.79%.Dec 9, 2022 ... Ginkgo Bioworks Stock Forecast - Analyst Ratings. Eight FactSet analysts have an Overweight consensus rating on DNA stock with a share price ...Get Ginkgo Bioworks Holdings Inc (DNA) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.Ginkgo trees, also known as maidenhair trees, are ancient and fascinating living fossils that have been around for millions of years. With their unique fan-shaped leaves and beautiful golden fall foliage, ginkgo trees make a stunning additi...With Ginkgo Bioworks Holdings stock trading at $1.46 per share, the total value of Ginkgo Bioworks Holdings stock (market capitalization) is $3.09B. Ginkgo Bioworks Holdings stock was originally listed at a price of $10.88 in Feb 24, 2021. If you had invested in Ginkgo Bioworks Holdings stock at $10.88, your return over the last 2 …Ginkgo Bioworks Holdings Inc stock has a Growth Score of 24, Estimate Revisions Score of 29 and Quality Score of 13. Comparing Ideaya Biosciences Inc and Ginkgo Bioworks Holdings Inc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your …
Ginkgo Acquisition. Ginkgo is acquiring Zymergen in an all-stock transaction that values Zymergen at approximately a 300 million USD market capitalization. The stated aim of the acquisition is to ...
May 22, 2023 · Ginkgo Bioworks' ( NYSE: DNA) first quarter results were something of a mixed bag, with continued progression on a number of metrics offset by rising costs and declining revenues. Ginkgo's success ... Is Ginkgo Bioworks a stock worth buying? When the stock began trading in September 2021, its valuation was around $15 billion. Today, it has a market capitalization of just $3.2 billion.Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report)’s stock price traded up 3.1% during trading on Friday . The stock traded as high as $1.35 and last traded at $1.33. 1,812,159 shares traded hands during trading, a decline of 91% from the average session volume of 20,609,900 shares. The stock had previously closed at […]Dec 1, 2023 · Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($0.37) to ($0.30) per share. Ginkgo Bioworks has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More. Aug 9, 2023 · Second Quarter 2023 Financial Highlights. Second quarter 2023 Total revenue of $81 million, down from $145 million in the comparable prior year period, a decrease of 44% primarily driven by the ... On that note, on August 29 Ginkgo Bioworks (DNA 3.88%) announced that it is joining forces with Alphabet, ... But does the work with Alphabet make it a buy, or is this stock still too risky to touch?
A high-level overview of Ginkgo Bioworks Holdings, Inc. (DNA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Ginkgo Bioworks' (NYSE: ... will probably keep Ginkgo's stock under pressure throughout 2023. Figure 9: Ginkgo Bioworks Revenue (Source: Created by author using data from Ginkgo Bioworks) ...
View the latest Ginkgo Bioworks Holdings Inc. (DNA) stock price, news, historical charts, analyst ratings and financial information from WSJ.As a member of the SPAC class of 2021, Ginkgo Bioworks ( NYSE: DNA) stock has seen its fair share of pummeling over the last few years. From an all-time high at ~$16 to the stock's current price ...There was plenty of action in Ginkgo Bioworks ( DNA 10.85%) stock on Thursday, but not the kind the company probably like. Investors sold out of the biotech following the publication of its latest ...Synthetic biology pioneer Ginkgo Bioworks agreed to go public today in a $17.5 billion SPAC deal. The Boston-based company will merge with Soaring Eagle Acquisition Corp., a blank-check firm ...Ginkgo Bioworks went public two years ago via a special purpose acquisition company. Deep losses and significant cash burn have made investors wary of investing in this risky stock. Special ...Ginkgo Bioworks' Q2 results were poor, with soft results in both the Cell Engineering and Biosecurity businesses. ... everyone will be scrambling to buy the stock at MUCH HIGHER prices. In 2022 ...Cathie Wood's ARK Innovation ETF (NYSEMKT: ARKK) is known for its investments in game-changing growth stocks backed by high-tech companies at the leading edge of science, making Ginkgo Bioworks ...1. Ginkgo Bioworks. Ginkgo Bioworks is a biotech company that went public through a special purpose acquisition company last year. The company has the backing of Bill Gates and can design and ...People have been waiting for this for a long time. And now it’s happening. People have been waiting for this for a long time. And now it’s happening. Money has started pouring out of the bond market. And more importantly, it’s pouring back ...
Ginkgo Bioworks Holdings Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a -272.3% profit margin. Year-over-year quarterly sales growth most recently was -16.6%.Ginkgo Bioworks (NYSE:DNA) Is among the more prominent stocks in the synthetic biology space. The company is located in Boston, Massachusetts, which is a leading hub in the biotechnology industry.Thesis. Ginkgo Bioworks ( NYSE: DNA) is a company with a lot of potential, but the risks seem to outweigh the reward at this juncture. The company is experiencing significant operating losses and ...Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results. $478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance ...Instagram:https://instagram. how much is atlanta braves stockstock broker ukreits with monthly dividendsbiotechnology stocks See the latest DNA Stock price for Ginkgo Bioworks Holdings Inc and NYSE: DNA stock rating, related news, valuation, dividends and more to help you make … nysearca schbishares core us aggregate bond etf You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading. future broker Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report)’s stock price rose 5.8% during mid-day trading on Friday . The stock traded as high as $1.46 and last traded at $1.46. Approximately 5,996,127 shares traded hands during trading, a decline of 71% from the average daily volume of 20,701,811 shares. The stock had previously closed […]Ginkgo Bioworks Holdings Inc’s stock is NA in 2023, NA in the previous five trading days and down 24.46% in the past year. Currently, Ginkgo Bioworks Holdings Inc does not have a price-earnings ratio. Ginkgo Bioworks Holdings Inc’s trailing 12-month revenue is $315.0 million with a -272.3% net profit margin. Year-over-year quarterly sales ...8,194,680. Aug 04 05:01 PM. open in yahoo open in reuters | open in marketwatch open in google open in EDGAR. DNA - Ginkgo Bioworks Holdings Inc - Stock screener for investors and traders, financial visualizations.